AstraZeneca cuts 600 US sales jobs in cost drive

AstraZeneca has cut about 600 jobs from its respiratory and immunology commercial teams in the United States, Bloomberg News reported on Friday, as the UK-based drugmaker pushes ahead with a three-year cost-savings programme.
The cuts were reported by Bloomberg, citing people familiar with the matter. Reuters, which carried the report, said it could not immediately verify it, and AstraZeneca declined to comment.
Part of a $1.5bn savings plan
The reductions follow AstraZeneca's announcement in late October that it planned to save about $1.5 billion a year and reinvest the money in its drug pipeline. Some of the employees affected by the restructuring are expected to be reassigned to other roles within the company, Bloomberg reported.
The move comes as chief executive Pascal Soriot seeks to reassure investors that AstraZeneca can meet its target of $80 billion in annual revenue by 2030, while drugmakers more broadly face growing scrutiny over the strength of their pipelines.
Respiratory and immunology in focus
The teams affected sell medicines for respiratory and immune conditions. That portfolio accounted for 16% of AstraZeneca's third-quarter revenue, at $2.5 billion, according to the report carried by KWSN.
AstraZeneca is headquartered in Cambridge and is one of Britain's largest listed companies. The cuts reported on Friday affect its commercial teams in the US rather than its UK operations, and no UK job losses have been announced as part of this round.